Alpha 2.0
Login Register
» Authors » Brandy Rutledge

Brandy Rutledge

Explore the profile of Brandy Rutledge including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 767
Followers 0
Related Specialties
Infectious Diseases
Endocrinology
Urology
Top 10 Co-Authors
Craig M Wilson
Kathleen Mulligan
Charles B Stephensen
Rohan Hazra
Peter L Havens
Nancy Liu
Marta D Van Loan
Patricia M Flynn
Bill G Kapogiannis
Jorge Lujan-Zilbermann
Published In
Clin Infect Dis
J Acquir Immune Defic Syndr
Diabetes Care
J Urol
JAMA Pediatr
Affiliations
Soon will be listed here.
Recent Articles
1.
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial
Havens P, Stephensen C, Van Loan M, Schuster G, Woodhouse L, Flynn P, et al.
Clin Infect Dis . 2017 Oct; 66(2):220-228. PMID: 29020329
Background: Tenofovir disoproxil fumarate (TDF) decreases bone mineral density (BMD). We hypothesized that vitamin D3 (VITD3) would increase BMD in youth receiving TDF. Methods: This was a randomized, double-blind, placebo-controlled...
2.
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States
Hosek S, Landovitz R, Kapogiannis B, Siberry G, Rudy B, Rutledge B, et al.
JAMA Pediatr . 2017 Sep; 171(11):1063-1071. PMID: 28873128
Importance: Adolescents represent a key population for implementing preexposure prophylaxis (PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for adults. Objective: To examine the safety...
3.
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis
Havens P, Stephensen C, Van Loan M, Schuster G, Woodhouse L, Flynn P, et al.
Clin Infect Dis . 2016 Dec; 64(3):317-325. PMID: 28013265
Background: We aimed to define the relative importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity. Methods: In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis...
4.
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM
Hosek S, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al.
J Acquir Immune Defic Syndr . 2016 Sep; 74(1):21-29. PMID: 27632233
Background: Young men who have sex with men (YMSM) are a key population for implementation of preexposure prophylaxis (PrEP) interventions. This open-label study examined adherence to PrEP and assessed sexual...
5.
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate
Havens P, Hazra R, Stephensen C, Kiser J, Flynn P, Wilson C, et al.
Antivir Ther . 2014 Feb; 19(6):613-8. PMID: 24535626
Background: Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding...
6.
Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein
Porter T, Li X, Stephensen C, Mulligan K, Rutledge B, Flynn P, et al.
Front Genet . 2013 Dec; 4:234. PMID: 24294218
Serum 25-hydroxyvitamin D [25(OH)D] is often deficient (<12 ng/ml) or insufficient (<20 ng/ml) in youth living with human immunodeficiency virus type 1 infection (YLH). Based on evidence from multiple genome-wide...
7.
The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men
Hosek S, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, et al.
J Acquir Immune Defic Syndr . 2013 Oct; 62(4):447-56. PMID: 24135734
Background: This study examined the feasibility of a combination prevention intervention for young men who have sex with men (YMSM), an anticipated target population for HIV preexposure prophylaxis (PrEP). Methods:...
8.
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Havens P, Kiser J, Stephensen C, Hazra R, Flynn P, Wilson C, et al.
Antimicrob Agents Chemother . 2013 Sep; 57(11):5619-28. PMID: 24002093
Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study...
9.
Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection
Havens P, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan M, et al.
J Clin Endocrinol Metab . 2012 Aug; 97(11):4004-13. PMID: 22933542
Context: Vitamin D deficiency and insufficiency occur frequently in youth with HIV infection, particularly among those receiving the antiretroviral drug efavirenz. Optimal vitamin D dosing for treatment is unclear. Objective:...
10.
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial
Havens P, Stephensen C, Hazra R, Flynn P, Wilson C, Rutledge B, et al.
Clin Infect Dis . 2012 Jan; 54(7):1013-25. PMID: 22267714
Background: The study goal was to determine the effect of vitamin D (VITD) supplementation on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and C-telopeptide (CTX)...